Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases

by Vandana Singh, Benzinga Editor

October 6, 2021 3:49 PM | 1 min read |

Centogene NV CNTG and Twist Bioscience Corporation TWST have signed a contract to develop and commercialize custom assay kits for rare diseases.
The financial details of the deal were not disclosed.
Related: Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs.
The product offering will combine Centogene's Bio/Databank with Twist Bioscience's library preparation and target enrichment capabilities to deliver multiple rare disease diagnosis and analysis assays.
Price Action: CNTG stock is up 0.39% at $10.30, while TWST stock is down 2.68% at $96.69 during the market session on the last check Wednesday.

Posted In: News Health Care Contracts General Briefs Diagnostics

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.